Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rapoport

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.
Clinical & Translational Immunology|May 4, 2022
Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccineKapil K Saharia, Jennifer S Husson, Silke V Niederhaus, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood|November 6, 2020
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapyJay Y Spiegel, Saurabh Dahiya, Michael D Jain, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Nature Medicine|October 18, 2005
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.
Clinical & Translational Immunology|May 4, 2022
Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccineKapil K Saharia, Jennifer S Husson, Silke V Niederhaus, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood|November 6, 2020
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapyJay Y Spiegel, Saurabh Dahiya, Michael D Jain, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Nature Medicine|October 18, 2005
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transferAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Pageof 18